LLY vs MRK
By Alex · Tickerpine
Eli Lilly and Company vs Merck & Co., Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | MRK |
|---|---|---|
| Price | $1,443.50 | $147.76 |
| Market cap | $1.29T | $364.26B |
| P/E ratio | 46.9 | 149.3 |
| ROE | 86.02% | 5.06% |
| Profit margin | 31.90% | 3.64% |
| Revenue growth | 38.60% | 4.70% |
| Dividend yield | 0.48% | 2.30% |
| Beta | 0.39 | 0.12 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs MRK in plain English
- LLY is the bigger company — about 3.5× the market cap of MRK.
- LLY is cheaper on earnings (P/E 46.9 vs 149.3).
- LLY earns a higher return on equity (86% vs 5%).
- LLY is growing revenue faster (39% vs 5%).
- MRK has the higher dividend yield (2.30% vs 0.48%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.